Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Apr;7(Suppl 2):S100-S102.
doi: 10.21037/tlcr.2018.02.09.

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option

Antonio Passaro  1 , Filippo de Marinis  1
Affiliations
Editorial

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option

Antonio Passaro et al. Transl Lung Cancer Res. 2018 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

References

    1. Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol 2018. [Epub ahead of print]. 10.2217/fon-2017-0636 - DOI - PubMed
    1. Passaro A, Pochesci A, Spitaleri G, et al. Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. Expert Rev Clin Pharmacol 2016:1-6. [Epub ahead of print]. - PubMed
    1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46. 10.1016/S1470-2045(11)70393-X - DOI - PubMed
    1. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42. 10.1016/S1470-2045(11)70184-X - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed